Diabetes, Metabolic Syndrome And Cardiovascular Disease
Table 6.1: Value Market Shares of Animal, Human and Modern Insulin, 1995-2010 101
Table 6.2: Worldwide Insulin Sales, 2008-2016 102
Table 6.3: Worldwide Insulin Sales and Market Share by World Region, 2011 102
Table 6.4: Estimated U.S. Retail Insulin Sales, 2011-2016 102
Table 6.5: Worldwide Insulin Sales and Market Share by Company, 2011 103 Table 6.6: U.S. Insulin Sales and Market Share by Company, 2011 103 Table 6.7: Insulins on the U.S. Market 105 Table 6.8: Pharmacokinetics of Therapeutic Insulins on the U.S. Market 106 Table 6.9: Pharmacokinetics of Short-Acting Insulins 108 Table 6.10: Pharmacokinetics of Rapid-Acting Insulins 108 Table 6.11: Pharmacokinetics of Intermediate-Acting Insulins 110 Table 6.12: Pharmacokinetics of Long-Acting Insulins 110 Table 6.13: Pharmacokinetics of Insulin Mixtures 112 Table 6.14: Status of Inhaled Insulin Products, 2011 117 Table 6.15: Key Drivers of the Type 2 Diabetes Insulin Market, 2012 122 Table 6.16: A Comparison of Existing Insulin Delivery Devices 123 Table 6.17: Insulin Pens 125 Table 6.18: Estimated Worldwide Demand for Insulin Injector Pens by Volume, 2012-2016 127 Table 6.19: Injection Aids 128 Table 6.20: Jet Injectors 130 Table 6.21: Control Averages by Treatment 131 Table 6.22: Reduced Risk for Various Diseases When Blood Glucose is Near Normal 131 Table 6.23: Leading Insulin Pump Manufacturers 132 Table 6.24: Comparison of Current External Insulin Pumps on the Market 132 Table 6.25: Insulin Infusion Sets 137 Table 6.26: Worldwide Insulin Pump Market, 2009-2016 141 Table 7.1: Advantages and Disadvantages of Newer Type 2 Diabetes Therapies 146 Table 7.2: Cells of the Pancreas 148 Table 7.3: Lipoprotein Risk Levels and Treatment Goals in Adult Patients with Diabetes 154 Table 7.4: Agents for Lowering Lipid Levels in Patients with Dyslipidemia 155 Table 7.5: Suggested Pharmacological Treatment Agents for Hypertension in Patients with Diabetes 156 Table 8.1: Criteria for the Diagnosis of Diabetes 159Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
